The equity award is structured under the firm's 2026 Inducement Plan, a mechanism reserved specifically for hiring individuals who were not previously employed by the San Diego-based diagnostics provider. According to company filings, the units carry a three-year vesting schedule, with equal annual installments contingent upon Young’s continued service at the company through each anniversary date.
QuidelOrtho, which operates across clinical chemistry and molecular testing sectors, utilizes these grants to secure executive talent as part of its broader strategy to integrate diagnostic insights into healthcare decision-making. The award is governed by the specific terms of the 2026 Inducement Plan and an individual RSU agreement.
Comments (0)
No comments yet. Be the first!